Last reviewed: June 11, 2026
Last updated: June 11, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) gained widespread attention for weight loss, yet many people remain unclear about its FDA approval status for this indication. The medication's path to weight management use involved multiple regulatory steps, separate from its original diabetes approval. Understanding these distinctions helps you make informed decisions about GLP-1 therapy options.
What Did the FDA Actually Approve Ozempic For?
The FDA approved Ozempic specifically for managing type 2 diabetes in December 2017. This initial approval focused on improving blood sugar control in adult patients with diabetes, not for weight loss as a standalone treatment. Ozempic became available as a once-weekly injection that helped reduce A1C levels and provided cardiovascular benefits in diabetic populations.
The weight loss effects emerged as a documented side benefit during diabetes trials, where researchers observed significant body weight reduction alongside improved glucose metabolism. However, this observation alone did not constitute FDA approval for obesity treatment. The distinction matters because regulatory approval requires specific clinical trials designed to measure a particular outcome—in this case, weight loss rather than blood sugar control.
The Regulatory Path for Semaglutide Weight Loss Treatment
Novo Nordisk pursued separate FDA approval specifically for weight management, leading to the approval of Wegovy (semaglutide) in June 2021. This represented the first GLP-1 medication approved by the FDA exclusively for chronic weight management in adults with obesity or overweight status with weight-related conditions. The Wegovy approval came after the STEP clinical trial program demonstrated sustained weight loss, with participants losing an average of 15% of their body weight over 68 weeks.
The key difference involves formulation, indication, and labeling: Ozempic carries FDA approval for diabetes, while Wegovy received approval specifically for weight loss. Both contain the same active ingredient (semaglutide), but the approved use cases differ. This regulatory distinction affects how healthcare providers prescribe the medications and influences insurance coverage decisions, though many physicians use off-label prescribing within their clinical judgment.
How Semaglutide Works in Your Body for Weight Management
Semaglutide functions as a GLP-1 receptor agonist, binding to receptors in your brain that regulate hunger signals and satiety. The medication slows gastric emptying, meaning food moves more slowly from your stomach to your intestines, creating a prolonged feeling of fullness. Additionally, semaglutide influences your body's energy expenditure and appears to affect reward pathways associated with food cravings, reducing the desire to eat.
Clinical evidence shows these mechanisms produce consistent weight loss across diverse populations. The STEP trials included over 4,500 adults, demonstrating that semaglutide-treated participants achieved approximately 15% average weight reduction compared to 3% in placebo groups. Beyond weight loss, participants experienced improvements in cardiovascular risk factors, blood pressure, and inflammatory markers—benefits that extend beyond aesthetics to genuine metabolic health gains.
PlexusDx Semaglutide Options and Accessibility
PlexusDx provides access to compounded semaglutide injections through licensed 503A compounding pharmacies, available across all 50 states without requiring insurance or membership fees. Compounded semaglutide delivers the same active ingredient as FDA-approved medications but originates from state-licensed compounding facilities that maintain strict quality standards. PlexusDx pricing starts at $149 per month, with HSA and FSA eligibility, making treatment financially accessible for patients seeking personalized weight management.
Your dose may need to go up as your treatment progresses, but your price won't—PlexusDx maintains flat monthly pricing across all commitment tiers. For patients interested in genetic insights about peptide pathways, the Precision Peptide Genetic Test can be added after your first month of treatment for $99, mapping 14 pathways and identifying genetic variants like GLP1R rs6923761 that influence your individual response to semaglutide therapy.
Understanding Off-Label Use Versus FDA-Approved Indications
Off-label prescribing occurs when licensed healthcare providers recommend FDA-approved medications for uses outside their formal indication, a legal and common practice in medicine. Many physicians have prescribed semaglutide off-label for weight loss since its diabetes approval in 2017, recognizing the clinical evidence supporting weight reduction benefits. When Wegovy received specific FDA approval for weight loss in 2021, this practice gained regulatory acknowledgment, though off-label use remains clinically valid.
The regulatory landscape reflects how medical science evolves: medications initially approved for one condition may demonstrate benefits for other conditions, and healthcare providers can recommend them based on clinical judgment and evidence. PlexusDx works with healthcare professionals who evaluate your individual health status, metabolic profile, and treatment goals to determine whether compounded semaglutide therapy aligns with your needs, regardless of your primary diagnosis.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic FDA-approved for weight loss specifically?
Ozempic received FDA approval for type 2 diabetes management, not weight loss. Wegovy (also semaglutide) is the FDA-approved medication specifically for chronic weight management. Both contain identical active ingredients but carry different approved indications. PlexusDx offers compounded semaglutide injections starting at $149/month, providing access to this evidence-based therapy for patients pursuing weight management goals.
How much weight can you lose with semaglutide therapy?
Clinical trials demonstrate average weight loss of approximately 15% of body weight over 68 weeks with semaglutide treatment, compared to 3% with placebo. Individual results vary based on genetics, lifestyle adherence, and metabolic factors. PlexusDx's Precision Peptide Genetic Test identifies your genetic predispositions across 14 peptide pathways, helping predict your individual response potential and optimize treatment personalization.
What makes PlexusDx semaglutide different from brand-name versions?
PlexusDx provides compounded semaglutide from licensed 503A compounding pharmacies at significantly lower costs ($149/month starting price) compared to brand medications, with no insurance requirement or membership fees. Compounded medications contain the same active ingredient but originate from state-regulated compounding facilities. Your flat monthly pricing covers all dose increases throughout your treatment journey.
Are compounded semaglutide medications safe?
Compounded semaglutide from licensed 503A pharmacies adheres to strict quality and safety standards established by state boards of pharmacy. These facilities must maintain rigorous sterility protocols, ingredient verification, and dosing accuracy. While compounded medications differ from FDA-approved branded versions, they represent a legal and clinically viable option when sourced from appropriate compounding pharmacies—as PlexusDx ensures.
Can genetic testing predict how well semaglutide will work for me?
PlexusDx's Precision Peptide Genetic Test examines key genetic variants including GLP1R rs6923761 and GIPR rs1800437, which influence how your body responds to semaglutide therapy. Understanding these predispositions helps your healthcare provider optimize your treatment plan and set realistic expectations. The test costs $99 as an add-on after your first month of treatment and maps 150+ genetic insights across 49 peptides.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Is a GLP-1 Probiotic and How Can It Enhance Your Metabolic Health?
Can You Take Ozempic If Breastfeeding? Navigating Weight Management Postpartum